Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Idenix Nixes Development of 2 Hepatitis C Drugs

Biotech firm Idenix Pharmaceuticals (NASDAQ: IDIX  ) announced Monday that it will not continue developing two of its pipeline drugs: hepatitis C therapy IDX184, which was in phase 2B clinical trial, and another HCV nucleotide polymerase inhibitor, IDX19368.

The FDA put IDX184 on hold in August of last year -- and placed IDX 19368 on clinical hold -- after poor results from a phase 2 trial from competitor Brystol-Myers Squibb's BMS-986094, which encountered "cardiac adverse events," according to Idenix's release. Idenix President and CEO Ron Renaud commented on the company's direction following the decision, saying in the release that it would continue to "maintain our strong presence in developing nucleotide polymerase inhibitors for HCV based on our broad discovery platform."


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2236859, ~/Articles/ArticleHandler.aspx, 4/26/2015 9:22:11 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!